The present Competitive Intelligence Report about antagonists of
the ErbB/Her receptor pathway provides a competitor evaluation in the field of
ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting
molecules for treatment of cancer as of July 2013. Purchase of the downloadable
pdf report includes a 6-month online access to the data of the report and any
updates since the publication date. Credentials to access the database will be
sent by e-mail and allow online work with the project data to print or export
an individual report.
To Read The Complete Report with TOC :-
Targeted treatment of EGF-R and Her2-positive cancers with
target specific antibodies has become an example of successful personalized
medicine. The commercial success of small molecule ErbB/Her receptor tyrosine
kinase inhibitors and EGF-R and Her2 targeted antibody therapy has spurred
the discovery and development of efficacy enhanced versions as well as of ErbB
dual or multi-target therapies.
The report includes a compilation of current active projects in
research and development of molecules targeting the receptors of the ErbB/Her
family. In addition the report lists company-specific R&D pipelines of
ErbB/Her receptor targeting molecular entities.
Competitor projects are listed in a tabular format providing
information on:
·
Drug
Codes,
·
Target
/ Mechanism of Action,
·
Class
of Compound,
·
Company,
·
Product
Category,
·
Indication,
·
R&D
Stage and
·
additional
comments with a hyperlink leading to the source of information.
To Buy a Copy Of This Report:-
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise
information about the pipeline of R&D projects for targets, diseases,
technologies and companies at low prices. The information is provided in a
tabular format and fully referenced.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment